GlassScriptPhysician profile
Joseph U Castro
NPI 1316252588
$13,454.68
in general payments reported to CMS, 2019-2025
55 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $1,336 · 2021: $2,256 · 2022: $2,066 · 2023: $2,397 · 2024: $2,352 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,404 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,404.10 |
| Education | $123.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,917.19 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,249.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,123.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,112.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $798.83 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.48 | 2019-2025 | Jardiance |
| Pfizer INC. | $682.31 | 2019-2025 | |
| Amgen INC. | $666.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $363.13 | 2019-2025 | Trintellix |
| Allergan, INC. | $339.89 | 2019-2020 | |
| Amarin Pharma, INC. | $287.07 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $227.39 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $220.24 | 2019-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Inspire Medical Systems, INC. | $220.22 | 2023-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $194.39 | 2022-2025 | Uptravi, Opsumit |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.